von Kleist S, Walker B, Walker R
Institute of Immunology of the University, Medical Faculty, Freiburg, Germany.
J Clin Lab Anal. 1996;10(4):184-92. doi: 10.1002/(SICI)1098-2825(1996)10:4<184::AID-JCLA3>3.0.CO;2-A.
To the already long list of existing tumor markers, a new marker has been recently added, the urinary gonadotropin peptide (UGP). This marker is determined in the urine of cancer patients and is considered to be particularly specific for ovarian carcinomas. The purpose of our study was to assess the specificity of UGP in a variety of malignancies other than ovarian carcinomas, e.g., breast, colonic, lung, and urogenital tumors (n = 50 each). The tumors were compared with benign lesions of the same organs. Urine samples of 50 healthy donors served as controls. The 450 urine samples were tested in duplicate using the UGP EIA-kit from Ciba Corning Diagnostics. All tumors were staged and histologically classified. For normalization in all samples, creatinine levels were determined. UGP was found in all tested tumors, however, with very low sensitivity of 20% in urogenital tumors, 46% in lung, and 30% or 27% in colon and breast carcinomas, respectively. The specificity of UGP was comprised between 100% (breast) and 88%. Clearly elevated UGP-concentrations were seen in postmenopausal women. A comparison of UGP with the optimal markers for each tumor system showed that UGP is not superior to these markers. However, we can confirm UGP as being an optimal marker for gynecological carcinomas.
在现有的众多肿瘤标志物中，最近又增加了一种新的标志物——尿促性腺激素肽（UGP）。这种标志物在癌症患者的尿液中进行检测，被认为对卵巢癌具有特别的特异性。我们研究的目的是评估UGP在除卵巢癌之外的多种恶性肿瘤中的特异性，例如乳腺癌、结肠癌、肺癌和泌尿生殖系统肿瘤（每种肿瘤各50例）。将这些肿瘤与相同器官的良性病变进行比较。50名健康供体的尿液样本作为对照。使用来自汽巴康宁诊断公司的UGP酶免疫分析试剂盒对450份尿液样本进行了重复检测。所有肿瘤均进行了分期并做了组织学分类。为了对所有样本进行标准化，测定了肌酐水平。在所有检测的肿瘤中均发现了UGP，然而，在泌尿生殖系统肿瘤中的敏感性非常低，为20%，在肺癌中为46%，在结肠癌和乳腺癌中分别为30%或27%。UGP的特异性在100%（乳腺癌）至88%之间。绝经后女性的UGP浓度明显升高。将UGP与每个肿瘤系统的最佳标志物进行比较表明，UGP并不优于这些标志物。然而，我们可以确认UGP是妇科癌症的一种最佳标志物。
